The FDA has approved naldemedine (Symproic, Shionogi Inc. and Purdue Pharma L.P.) for the treatment of opioid-induced constipation in adult patients with chronic noncancer pain.
Naldemedine, which will be available as a once-daily 0.2-mg tablet, was recently approved for the treatment of OIC. The drug is a Schedule II controlled substance; however, Shionogi has asked the Drug Enforcement Administration to change its classification.
“We believe Symproic will offer a new therapeutic option to